Targeting the spliceosome for cutaneous squamous cell carcinoma therapy: a role for c-MYC and wild-type p53 in determining the degree of tumour selectivity
Open Access
- 1 May 2018
- journal article
- Published by Impact Journals, LLC in Oncotarget
- Vol. 9 (33) , 23029-23046
Abstract
Targeting the spliceosome for cutaneous squamous cell carcinoma therapy: a role for c-MYC and wild-type p53 in determining the degree of tumour selectivity Targeting the spliceosome for cutaneous squamous cell carcinoma therapy: a role for c-MYC and wild-type p53 in determining the degree of tumour selectivityKeywords
This publication has 106 references indexed in Scilit:
- The P-body component USP52/PAN2 is a novel regulator of HIF1A mRNA stabilityBiochemical Journal, 2013
- Pre-mRNA processing factors meet the DNA damage responseFrontiers in Genetics, 2013
- RNA surveillance is required for endoplasmic reticulum homeostasisProceedings of the National Academy of Sciences, 2012
- Integrative mRNA profiling comparing cultured primary cells with clinical samples reveals PLK1 and C20orf20 as therapeutic targets in cutaneous squamous cell carcinomaOncogene, 2011
- Sudemycins, Novel Small Molecule Analogues of FR901464, Induce Alternative Gene SplicingACS Chemical Biology, 2011
- An Alternative Splicing Network Links Cell-Cycle Control to ApoptosisCell, 2010
- A Genome-wide siRNA Screen Reveals Diverse Cellular Processes and Pathways that Mediate Genome StabilityMolecular Cell, 2009
- Suppression of the Deubiquitinating Enzyme USP5 Causes the Accumulation of Unanchored Polyubiquitin and the Activation of p53Journal of Biological Chemistry, 2009
- Incorporation of 5-fluorouracil into U2 snRNA blocks pseudouridylation and pre-mRNA splicing in vivoNucleic Acids Research, 2006
- A Regulatory Mechanism That Detects Premature Nonsense Codons in T-cell Receptor Transcripts in Vivo Is Reversed by Protein Synthesis Inhibitors in VitroJournal of Biological Chemistry, 1995